Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

¹M.D. Asistant Professor, Istanbul Medipol Hospital, Eye Clinic, Istanbul/TURKEY
²M.D. Istanbul Medipol Hospital, Eye Clinic, Istanbul/TURKEY
³M.D. Associate Professor, Istanbul Medipol Hospital, Eye Clinic, Istanbul/TURKEY The selective third-generation aromatase inhibitors (anastrozole, letrozole, and exemestane ) have been used for more than ten years in worldwide for the standard of therapy for hormone-receptor-positive breast cancer in postmenopausal women. The authors are in agreement on the effectiveness of this drug in breast cancer, but the type and number of side effects have been quite variable. Based on analysis of OCT retinal thickness data, it is likely that aromatase inhibitors increases the tractional force between the vitreous and retina, and this might be at increased risk for traction-related vision loss. We report a 56- years-old woman with bilateral vitreomacular traction sydrome treated with anastrozole more than two years to decrease recurrence of breast cancer. Keywords : Anastrozole, vitreomacular traction, optic cohorens tomography